The clinical catalyst (FDA alignment on Phase 3 design and strong efficacy data) dominates the EPS miss. Watch for EULAR 2026 presentations (June) and Phase 3 trial initiation in H2 2026. The cash runway into Q2 2027 provides a sufficient buffer for the registrational trial. Any safety or efficacy readout from the broader autoimmune dataset could further re-rate the stock.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $10.89entry
- T+1 · 6mo ago −2.66%α −2.89% · $10.60
- T+5 · 6mo ago −1.93%α −3.39% · $10.68
- T+20 · 5mo ago −37.10%α −37.12% · $6.85
- T+60 · 3mo ago +1.65%α −3.19% · $11.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while revenue remained $0. The net loss widened to $23.5M from $20.3M a year ago. However, the stock is likely to move on the positive clinical catalyst: FDA alignment on a single Phase 3 registrational trial for AlloNK in refractory RA, with 71% ACR50 response at six months in initial data, supporting a potential path to market.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.95 vs consensus -$0.84 (13.1% miss)
- Net loss $23.5M vs $20.3M YoY, driven by higher R&D spend ($19.3M vs $17.1M)
- Cash runway into Q2 2027 with $86.8M in cash and investments
- FDA alignment on single Phase 3 registrational trial for AlloNK in refractory RA; trial initiation H2 2026
- 71% ACR50 response at six months in refractory RA patients from Phase 2a basket trial
- No CRS, ICANS, or treatment discontinuations reported; outpatient administration profile
- Multiple abstracts accepted at EULAR 2026, including a late-breaking oral presentation
Financial Impact
EPS miss of $0.11 vs consensus; net loss increased $3.2M YoY; cash burn rate ~$7.8M/month
Risk Factors
- Phase 3 trial may fail to replicate Phase 2a efficacy results
- FDA minutes from alignment meeting could differ from Artiva's interpretation
- Cash burn may require dilutive financing before Q2 2027 if trial costs exceed expectations
- Competition from CAR-T therapies in autoimmune indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290961 |
Track record
33 reports on ARTV
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers